Clinical Trials Directory

Trials / Completed

CompletedNCT04907149

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

A Phase 1, Open-label Study to Investigate the Pharmacokinetics and Metabolism of GLPG3970 in Healthy Male Subjects Following a Single Oral Dose of GLPG3970 Relative to an Intravenous [14C]GLPG3970 Microtracer and Single Oral [14C]GLPG3970 Administration

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Galapagos NV · Industry
Sex
Male
Age
30 Years – 64 Years
Healthy volunteers
Accepted

Summary

A study in healthy male volunteers to assess how the radiolabelled test medicine is taken up and broken down by the body when given by short infusion into a vein and when given by the mouth in the form of a tablet and an oral solution.

Conditions

Interventions

TypeNameDescription
DRUGGLPG3970 film-coated tabletParticipants will receive a single oral dose of GLPG3970.
DRUG[14C]GLPG3970 solution for infusionParticipants will receive an i.v. microtracer microdose.
DRUG[14]GLPG3970 oral solutionParticipants will receive a single oral dose \[14C\]GLPG3970.

Timeline

Start date
2021-06-07
Primary completion
2021-07-12
Completion
2021-07-12
First posted
2021-05-28
Last updated
2021-07-23

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT04907149. Inclusion in this directory is not an endorsement.

Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970 (NCT04907149) · Clinical Trials Directory